Cargando…

The role of BRAF V600 mutation in melanoma

BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ascierto, Paolo A, Kirkwood, John M, Grob, Jean-Jacques, Simeone, Ester, Grimaldi, Antonio M, Maio, Michele, Palmieri, Giuseppe, Testori, Alessandro, Marincola, Francesco M, Mozzillo, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3391993/ https://www.ncbi.nlm.nih.gov/pubmed/22554099 http://dx.doi.org/10.1186/1479-5876-10-85

Ejemplares similares

Do BRAF inhibitors select for populations with different disease progression kinetics?
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a (V600E)BRAF inhibitor): a case report
por: Simeone, Ester, et al.
Publicado: (2012)

Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations
por: Gentilcore, Giusy, et al.
Publicado: (2013)

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients
por: Simeone, Ester, et al.
Publicado: (2015)

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
por: Colombino, Maria, et al.
Publicado: (2013)

Melanoma: From Research to Treatment
por: Ascierto, Paolo A., et al.
Publicado: (2011)

The immune‐related role of BRAF in melanoma
por: Tomei, Sara, et al.
Publicado: (2014)

The immune-related role of BRAF in melanoma
por: Tomei, Sara, et al.
Publicado: (2015)

Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment
por: Ascierto, Paolo A, et al.
Publicado: (2010)

Report from the second MIB (Melanoma Independent Board) Conference, 27–28 October 2014
por: Testori, Alessandro, et al.
Publicado: (2015)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
por: Rubinstein, Jill C, et al.
Publicado: (2010)

The role of spectrophotometry in the diagnosis of melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2010)

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
por: Simeone, Ester, et al.
Publicado: (2021)

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients
por: Grimaldi, Antonio Maria, et al.
Publicado: (2015)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
por: Ascierto, Paolo A., et al.
Publicado: (2019)

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
por: Grimaldi, Antonio M, et al.
Publicado: (2014)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”, Napoli, December 5th-8th 2013
por: Ascierto, Paolo A, et al.
Publicado: (2014)

Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma
por: Palmieri, Giuseppe, et al.
Publicado: (2006)

Melanoma: the role of surgery in the era of new therapies
por: Mozzillo, Nicola, et al.
Publicado: (2014)

MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAF(V600E) Mutation Detected in Circulating-Free DNA
por: Salemi, Rossella, et al.
Publicado: (2018)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013)

Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
por: Sigalotti, L, et al.
Publicado: (2011)

Main roads to melanoma
por: Palmieri, Giuseppe, et al.
Publicado: (2009)

Serious haematological toxicity during and after ipilimumab treatment: a case series
por: Simeone, Ester, et al.
Publicado: (2014)

FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5(th)–6 (th)2011”
por: Ascierto, Paolo A, et al.
Publicado: (2012)

What have we learned from cancer immunotherapy in the last 3 years?
por: Ascierto, Paolo A, et al.
Publicado: (2014)

Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis
por: Caracò, Corrado, et al.
Publicado: (2013)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma
por: Dummer, Reinhard, et al.
Publicado: (2022)

Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)
por: Aglietta, Massimo, et al.
Publicado: (2021)

Vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
por: Chapman, P B, et al.
Publicado: (2017)

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation–positive melanoma
por: Dréno, Brigitte, et al.
Publicado: (2018)

Loss of Spry1 reduces growth of BRAF(V600)-mutant cutaneous melanoma and improves response to targeted therapy
por: Montico, Barbara, et al.
Publicado: (2020)

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
por: Ascierto, Paolo A, et al.
Publicado: (2011)

MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
por: Bifulco, Carlo, et al.
Publicado: (2014)

Targeted Therapy for Melanomas Without BRAF V600 Mutations
por: Menzer, Christian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g8e10pnktj37ok08sjff25vlq1